IsomAb Names Development Candidate for PAD and Partners with Pfizer

IsomAb Ltd, a biotechnology firm based in the UK, has recently declared the nomination of a Development Candidate for treating peripheral arterial disease (PAD). The candidate, ISM-001, is an innovative therapeutic antibody aimed at neutralizing VEGF-A165b, an anti-angiogenic VEGF-A splice isoform that inhibits new blood vessel growth, leading to chronic limb-threatening ischemia (CLTI). This advancement marks the beginning of a series of pre-clinical studies that are essential for obtaining approval to commence first-in-human clinical trials.

In a strategic move to bolster the development of ISM-001, IsomAb has entered into a collaboration with Pfizer Ignite. Pfizer Ignite is an all-encompassing service for biotech firms focusing on therapeutics within Pfizer's key strategic domains. By leveraging Pfizer's extensive research and development capabilities, scale, and expertise, Pfizer Ignite aids in fast-tracking the development of breakthrough therapies. Despite this collaboration, IsomAb will maintain full decision-making authority and retain all rights to the ISM-001 program.

Peripheral arterial disease (PAD) affects over 230 million individuals globally. The primary risk factors for PAD include type 2 diabetes, obesity, high blood pressure, and elevated cholesterol levels. The progression to CLTI in patients often results from inadequate primary care and the lack of effective treatments, culminating in a significant risk of amputation, estimated at 25% within a year.

Jackie Turnbull, CEO of IsomAb Ltd, emphasized the significance of the announcement, describing it as a critical milestone for the company. Turnbull expressed optimism regarding the potential of ISM-001 as a pioneering treatment for PAD, particularly for type 2 diabetics with CLTI who face a high risk of amputation. Highlighting the severe consequences of limb loss and its impact on patients' lives, Turnbull underscored the limited treatment options currently available. She expressed pride in partnering with Pfizer, given their strong commitment, extensive capabilities, and expertise in developing new therapeutics. Turnbull looks forward to harnessing the full potential of ISM-001 in transforming the treatment landscape for PAD patients.

Kathy Fernando, Senior Vice President and Global Head of Pfizer Ignite, reiterated the commitment to the collaboration with IsomAb, aiming to advance the preclinical and IND-enabling studies for ISM-001. Fernando highlighted Pfizer's robust history in developing and conducting trials for vascular diseases. She emphasized the plan to utilize this expertise to support and guide IsomAb in translating their compelling scientific research into a promising new treatment option for PAD patients.

This collaboration between IsomAb and Pfizer Ignite signifies a concerted effort to address a critical unmet need in PAD treatment, offering hope for innovative therapeutic solutions to improve the lives of millions affected by this debilitating condition.